Divis Laboratories Stock Screener | Share Price & Fundamental Analysis
DIVISLAB
Pharmaceuticals
Screen Divis Laboratories share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹6642.50
▲
279.00 (4.38%)
Share Price BSE
₹6644.20
▲
281.20 (4.42%)
Market Cap
₹176,337.50 Cr.
P/E Ratio (TTM)
67.97
P/B Ratio
10.96
EPS (TTM)
₹82.53
Dividend Yield
0.47%
Debt to Equity
-
52W High
₹6983.50
52W Low
₹5258.95
Operating Margin
33.00%
Profit Margin
24.09%
Revenue (TTM)
₹2,860.00
EBITDA
₹1,033.00
Net Income
₹689.00
Total Assets
₹16,932.00
Total Equity
₹14,969.00
Divis Laboratories Share Price History - Stock Screener Chart
Screen DIVISLAB historical share price movements with interactive charts. Analyze price trends and patterns.
Divis Laboratories Company Profile - Fundamental Screener
Screen Divis Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for DIVISLAB shares.
Divi's Laboratories Ltd is a leading pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals. The company operates globally with a presence in over 100 countries and has six manufacturing facilities. It offers both generic and custom synthesis services for pharmaceutical companies, supporting product development...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Ramesh B V Nimmagadda
ISIN
INE361B01024
Website
https://www.divislabs.com
Divis Laboratories Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen DIVISLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 16,932 | 15,470 | 14,439 | 13,375 | 10,774 | 8,536 | 8,038 | 6,786 | 6,159 | 4,902 |
| Current Assets | 10,081 | 9,675 | 9,312 | 8,352 | 6,175 | 4,680 | 4,650 | 4,535 | 4,011 | 3,027 |
| Fixed Assets | 5,442 | 4,739 | 4,723 | 4,325 | 3,704 | 2,782 | 2,088 | 1,996 | 1,559 | 1,439 |
| Liabilities | ||||||||||
| Total Liabilities | 16,932 | 15,470 | 14,439 | 13,375 | 10,774 | 8,536 | 8,038 | 6,786 | 6,159 | 4,902 |
| Current Liabilities | 511 | 621 | 571 | 451 | 367 | 299 | 234 | 208 | 142 | 89 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 14,969 | 13,571 | 12,767 | 11,728 | 9,295 | 7,310 | 6,957 | 5,925 | 5,357 | 4,293 |
| Share Capital | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
| Reserves & Surplus | 14,916 | 13,518 | 12,714 | 11,675 | 9,242 | 7,257 | 6,904 | 5,872 | 5,304 | 4,240 |
Screen DIVISLAB income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,860 | 2,529 | 2,671 | 2,401 | 2,444 | 2,197 | 2,382 | 1,950 | 1,995 | 1,859 | 2,017 | 1,821 | 1,935 | 2,343 | 2,571 |
| Expenses | 1,827 | 1,681 | 1,699 | 1,576 | 1,622 | 1,496 | 1,572 | 1,366 | 1,430 | 1,274 | 1,464 | 1,299 | 1,234 | 1,406 | 1,414 |
| EBITDA | 1,033 | 848 | 972 | 825 | 822 | 701 | 810 | 584 | 565 | 585 | 553 | 522 | 701 | 937 | 1,157 |
| Operating Profit % | 33.00% | 30.00% | 34.00% | 32.00% | 31.00% | 29.00% | 32.00% | 26.00% | 25.00% | 28.00% | 25.00% | 24.00% | 33.00% | 38.00% | 44.00% |
| Depreciation | 113 | 112 | 107 | 99 | 99 | 97 | 95 | 95 | 95 | 93 | 87 | 87 | 86 | 85 | 81 |
| Interest | 8 | 3 | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 912 | 733 | 864 | 726 | 722 | 604 | 713 | 489 | 469 | 492 | 466 | 435 | 615 | 852 | 1,076 |
| Tax | 223 | 188 | 202 | 137 | 212 | 174 | 175 | 131 | 121 | 136 | 145 | 129 | 122 | 150 | 181 |
| Net Profit | 689 | 545 | 662 | 589 | 510 | 430 | 538 | 358 | 348 | 356 | 321 | 306 | 493 | 702 | 895 |
| EPS | 25.97 | 20.49 | 24.93 | 22.20 | 19.20 | 16.20 | 20.25 | 13.50 | 13.11 | 13.41 | 12.09 | 11.56 | 18.60 | 26.44 | 33.70 |
Divis Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen DIVISLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,653 | 1,261 | 2,460 | 1,912 | 1,947 | 1,216 | 954 | 776 | 1,150 | 1,038 |
| Investing Activities | -804 | -269 | -2,708 | -2,195 | 75 | -84 | -685 | -478 | -1,140 | -406 |
| Financing Activities | -799 | -799 | -797 | -532 | -35 | -1,091 | -246 | -314 | 2 | -631 |
| Net Cash Flow | 50 | 193 | -1,045 | -816 | 1,987 | 41 | 23 | -17 | 13 | 0 |
Screen DIVISLAB shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 51.89% | 51.89% | 51.89% | 51.92% | 51.90% | 51.89% | 51.89% | 51.94% |
| FII Holding | 18.01% | 19.74% | 19.39% | 14.68% | 16.16% | 17.25% | 17.99% | 0.00% |
| DII Holding | 20.71% | 19.05% | 19.76% | 22.21% | 21.77% | 21.06% | 20.54% | 21.07% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 7.17% | 7.05% | 6.78% | 8.69% | 7.77% | 7.41% | 7.32% | 9.61% |
| Other Holding | 2.22% | 2.27% | 2.18% | 2.50% | 2.41% | 2.39% | 2.26% | 17.37% |
| Shareholder Count | 267,755 | 259,825 | 249,634 | 347,629 | 298,310 | 278,899 | 280,601 | 433,621 |
Divis Laboratories Dividend Screener - Share Yield Analysis
Screen DIVISLAB dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹30.00 | 0.47% |
| 2024-March | ₹30.00 | 0.52% |
| 2023-March | ₹30.00 | 0.87% |
| 2022-March | ₹30.00 | 1.06% |
| 2021-March | ₹20.00 | 0.45% |
| 2020-March | ₹16.00 | 0.44% |
| 2019-March | ₹16.00 | 0.80% |
| 2018-March | ₹10.00 | 0.59% |
| 2017-March | ₹10.00 | 0.92% |
Divis Laboratories Index Membership - Market Screener Classification
Screen DIVISLAB by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Divis Laboratories Market Events Screener - Corporate Actions
Screen DIVISLAB market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | 4.53% |
| 2025-08-11 | 2025-08-11 | Annual General Meeting | NA | -5.90% |
| 2025-08-06 | 2025-08-06 | Quarterly Result Announcement | NA | -3.16% |
| 2025-07-25 | 2025-07-25 | Dividend | ₹ 30.00 /share | 5.38% |
| 2025-05-17 | 2025-05-17 | Quarterly Result Announcement | NA | 2.23% |
| 2025-02-03 | 2025-02-03 | Quarterly Result Announcement | NA | -3.47% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | 2.20% |
| 2024-08-12 | 2024-08-12 | Annual General Meeting | NA | 17.16% |
| 2024-08-02 | 2024-08-02 | Dividend | ₹ 30.00 /share | 19.38% |
| 2023-08-11 | 2023-08-11 | Dividend | ₹ 30.00 /share | 20.91% |
| 2022-08-11 | 2022-08-12 | Dividend | ₹ 30.00 /share | -8.33% |
| 2021-08-17 | 2021-08-20 | Dividend | ₹ 20.00 /share | 19.22% |
Divis Laboratories Competitors Screener - Peer Comparison
Screen DIVISLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 422,331 | 39.59 | 54,729 | 9.71% | 10,980 | 53.13 |
| Divis Laboratories | 176,338 | 67.97 | 9,712 | 18.67% | 2,191 | 63.15 |
| Torrent Pharmaceuticals | 133,239 | 61.20 | 11,539 | 6.99% | 1,911 | 71.28 |
| Cipla | 123,654 | 22.59 | 28,410 | 7.12% | 5,291 | 57.84 |
| Dr Reddys Laboratories | 104,846 | 18.17 | 33,741 | 16.73% | 5,725 | 46.16 |
| Lupin | 98,198 | 21.84 | 22,910 | 13.74% | 3,306 | 63.46 |
| Zydus Life Science | 93,685 | 18.44 | 23,511 | 18.55% | 4,615 | 54.52 |
| Mankind Pharma | 92,501 | 51.05 | 12,744 | 20.90% | 2,007 | 56.13 |
| Aurobindo Pharma | 71,514 | 20.50 | 32,346 | 9.43% | 3,484 | 60.21 |
| Alkem Laboratories | 67,620 | 27.57 | 13,458 | 3.70% | 2,216 | 55.49 |
Divis Laboratories Company Announcements - News Screener
Screen DIVISLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-05 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2026-01-02 | Closure of Trading Window | View |
| 2025-11-14 | Regulation 30 Disclosure - US-FDA Inspection Of CompanyS Unit-I Manufacturing Facility At Lingojigudem Village Yadadri Bhuvanagiri District Telangana India | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-07 | Board Meeting Outcome for Outcome Of Board Meeting | View |
| 2025-10-29 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-27 | Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025. | View |
| 2025-10-17 | Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |
| 2025-10-17 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |
| 2025-10-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-30 | Closure of Trading Window | View |
| 2025-09-05 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-08-30 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-12 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-08-11 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |